C12N 2760/20243
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2760/20243 (Viral genome or elements thereof as genetic vector) appears on 93 US grants and 198 published applications in this corpus.
Search patents in C12N- Granted patents
- 93
- Published applications
- 198
- Assignees
- 80
- Inventors
- 305
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 1 | 5 |
| 2004 | 1 | 1 |
| 2005 | 0 | 0 |
| 2006 | 1 | 2 |
| 2007 | 0 | 5 |
| 2008 | 0 | 1 |
| 2009 | 1 | 1 |
| 2010 | 1 | 6 |
| 2011 | 4 | 6 |
| 2012 | 3 | 6 |
| 2013 | 1 | 6 |
| 2014 | 2 | 9 |
| 2015 | 1 | 1 |
| 2016 | 5 | 6 |
| 2017 | 10 | 16 |
| 2018 | 8 | 5 |
| 2019 | 8 | 18 |
| 2020 | 8 | 8 |
| 2021 | 6 | 16 |
| 2022 | 4 | 10 |
| 2023 | 7 | 17 |
| 2024 | 4 | 27 |
| 2025 | 8 | 15 |
| 2026 | 7 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Oncolytic virus in combination with immune checkpoint inhibitor for treating tumors15 Sep 2026US 12,734,202 B2Joint Biosciences (Sh) Ltd.
- Sequential heterologous boost oncolytic viral immunotherapy25 Aug 2026US 12,714,733 B2Children's Hospital of Eastern Ontario Research Institute Inc.
- Methods and materials for treating cancer4 Aug 2026US 12,697,361 B2Mayo Foundation for Medical Education and Research
- Compositions and methods of use of oncolytic virus like vesicles17 Mar 2026US 12,577,585 B2Carogen Corporation
- Detection assays for coronavirus neutralizing antibodies20 Jan 2026US 12,529,699 B2Regeneron Pharmaceuticals, Inc.
- Transduction aids and transduction methods27 Aug 2026US 2026/0250635 A1
- Mutant vsvg and targeting vector13 Aug 2026US 2026/0234198 A1Shenzhen Genocury Biotech Co., Ltd.
- Stabilization of virus-based therapeutic agent14 May 2026US 2026/0130983 A1Elarex Inc.
- Macrophage depletion and vesicular stomatitis virus for treatment of cancer7 May 2026US 2026/0125459 A1Boehringer Ingelheim International GmbH
- Recombinant rhabdovirus encoding for a gasdermin30 Apr 2026US 2026/0117200 A1Boehringer Ingelheim International GmbH
Most cited
By later US patents
- Attenuation of negative stranded RNA viruses by rearrangement of genes and uses thereof29US 6,136,585 AThe UAB Research Foundation · 2000
- Recombinant Rhabdovirus containing a heterologous fusion protein16US 6,497,873 B1The University of Tennessee Research Corporation · 2002
- Glucagon-like-peptide-2 (GLP-2) analogues14US 7,563,770 B2Zealand Pharma A/S · 2009
- Methods of treating chemotherapy-induced diarrhea/mucositis using glucagon-like-peptide-2(GLP-2)analogues11US 7,745,403 B2Zealand Pharma A/S · 2010
- Treatment of inflammatory bowel disease using glucagon-like-peptide-2 (GLP-2) analogues10US 8,163,696 B2Zealand Pharma A/S · 2012